Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 884 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Coagulation Disorders Clear all
Completed Phase 4 Interventional Results available

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

NCT00586521
View directory record Official record
Conditions
Hematologic Disease, Hemophilia A
Interventions
Kogenate (BAY14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
30 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 14, 2026, 6:16 PM EDT
Completed No phase listed Observational

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

NCT04091386
View directory record Official record
Conditions
Hemophilia A
Interventions
Damoctocog alfa pegol (Jivi, BAY94-9027)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Orange, California • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 14, 2026, 6:16 PM EDT
Withdrawn Phase 3 Interventional

Study of a Gene Therapy Treatment for Hemophilia A

NCT06297486
View directory record Official record
Conditions
Hemophilia A
Interventions
SPK-8011
Genetic
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
27
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 14, 2026, 6:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Objective Measures of Place-Based Physical Activity

NCT01886261
View directory record Official record
Conditions
Physical Activity
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

NCT01425723
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 14, 2026, 6:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea

NCT00936481
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera

NCT01243073
View directory record Official record
Conditions
Essential Thrombocythemia, Polycythemia Vera
Interventions
Imetelstat
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Duarte, California • Orlando, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 14, 2026, 6:16 PM EDT
Terminated Phase 3 Interventional Results available

Early Prophylaxis Immunologic Challenge (EPIC) Study

NCT01376700
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 1 Year · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Indianapolis, Indiana • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 14, 2026, 6:16 PM EDT
Withdrawn Not applicable Interventional

Thromboelastography to Study Burn Coagulopathy

NCT06879509
View directory record Official record
Conditions
Burn, Coagulation, Blood
Interventions
Thromboelastography
Diagnostic Test
Lead sponsor
Francesco Egro
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Ketorolac on Platelet Function Post-Cesarean Delivery

NCT03805607
View directory record Official record
Conditions
Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac Tromethamine 30 MG/ML, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

NCT03275454
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
BIVV009 6.5 grams, BIVV009 7.5 grams
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Georgetown, District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 4 Interventional Results available

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag Oral Tablet
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 14, 2026, 6:16 PM EDT
Recruiting No phase listed Observational

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

NCT07071051
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 14, 2026, 6:16 PM EDT
Active, not recruiting No phase listed Observational

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201
View directory record Official record
Conditions
Hemophilia A
Interventions
Damoctocog alfa pegol (Jivi, Bay94-9027)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Mobile, Alabama • Phoenix, Arizona • Davis, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 6:16 PM EDT
Recruiting No phase listed Observational

Evaluation of Hemostasis in Bleeding and Thrombotic Disorders

NCT00178594
View directory record Official record
Conditions
Blood Coagulation Disorders, Inherited, Thrombotic Disorder
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 98 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2028
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 14, 2026, 6:16 PM EDT
Withdrawn Not applicable Interventional

FFP Versus PCC in Intracranial Hemorrhage

NCT02429453
View directory record Official record
Conditions
Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions
Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma
Drug · Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 14, 2026, 6:16 PM EDT
Completed No phase listed Observational

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

NCT01970930
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia
Interventions
Blood specimen
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

NCT02234323
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 5 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

NCT02035605
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 14, 2026, 6:16 PM EDT
Terminated No phase listed Observational Results available

Understanding Hemophilia A and B Drug Dosage Administration Patterns

NCT03248141
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Hemophilia B standard half-life, Hemophilia B extended half-life, Hemophilia A standard half-life, Hemophilia A extended half-life
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Gainesville, Florida • Las Vegas, Nevada • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 14, 2026, 6:16 PM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Prevention Trial

NCT04303559
View directory record Official record
Conditions
Hemophilia A Without Inhibitor
Interventions
Eloctate Injectable Product, Emicizumab Injection [Hemlibra]
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
4 Months to 4 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Little Rock, Arkansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 14, 2026, 6:16 PM EDT
Recruiting Phase 2 Interventional

A Randomized Multicenter Study for Isolated Skin Vasculitis

NCT02939573
View directory record Official record
Conditions
Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Interventions
Colchicine, Dapsone, Azathioprine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
12
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 14, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers

NCT01589666
View directory record Official record
Conditions
Coagulation Defects
Interventions
Spray-dried S/D-treated Plasma, Spray-dried S/D-treated plasma
Biological · Drug
Lead sponsor
Entegrion, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 14, 2026, 6:16 PM EDT